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Supersaturation of four structurally related crystalline carboxylic acid drugs (naproxen, 
indomethacin, ibuprofen, and etodolac) was studied in aqueous acidic conditions at 37ºC in the 
absence and presence of pre-dissolved HPMC. A solvent-shift method was used in which drug-
containing DMSO solution concentrates were prepared with each molecule and carefully added 
to aqueous acidic solutions while stirring. Tests were performed to measure drug dissolved 
concentration as a function of time and to characterize any resulting precipitate. Supersaturation 
was observed for all four model carboxylic acid drugs in the presence of HPMC-containing 
aqueous acidic solutions. When precipitation occurred the isolated solid drug was characterized 
and shown to increase in amorphous character or produce completely amorphous solid. The 
solution and solid-state data suggests that the mechanisms by which HPMC induces 
supersaturation include both increased equilibrium solubility and crystallization inhibition in the 
presence of HPMC in naproxen, indomethacin, and ibuprofen. In etodolac, there was no 
observed significant increase of equilibrium solubility, and only a loss of crysallinity upon 
precipitation in kinetic solubility studies. Additional studies with etodolac showed that the grade 
and viscosity of HPMC did not significantly affect the degree of supersaturation maintained. 
However, an increased initial degree of supersaturation of etodolac results in a decreased onset 
time of precipitation. Within the range studied the optimal degree of supersaturation of etodolac 
was 5 in which no precipitation occurred, at a degree of supersaturation of  7 precipitation 
occurred after 3 hours, whereas at a degree of supersaturation of 10 precipitation occurred 
immediately. The studies suggest that the solubilizing and supersaturating-promoting effects of 
HPMC may be useful in designing preclinical, clinical and commercial formulations and drug 




3.  PURPOSE 
The purpose of the current work is to explore the variables by which four crystalline carboxylic 
acid drug molecules show supersaturation behavior in the presence of hydroxypropyl 
methylcellulose (HPMC) under aqueous acidic pH conditions. Four model compounds were 
evaluated: naproxen, indomethacin, ibuprofen, and etodolac. The molecular structures are shown 
in Figure 1. Experiments were performed by carefully adding a concentrated drug in DMSO 
solution into a stirred aqueous acidic solution with and without dissolved HPMC, and then 
observing for precipitation, measuring dissolved drug concentration, and characterizing the 
isolated drug precipitate. All compounds were evaluated at an initial degree of supersaturation of 
five relative to their equilibrium solubility, and were found to show supersaturation behavior in 
the presence of HPMC.  In addition, the precipitates in the presence of HPMC showed a 
significant loss in crystallinity relative to the starting crystalline model drugs. The mechanisms 
by which HPMC promotes supersaturation were found to be due to be mainly crystallization or 
nucleation inhibition, and in part byincreased equilibrium solubility in the presence of HPMC.   
Of the compounds studied, etodolac was selected for further study.  Specifically, the effects of 
various viscosities and grades of HPMC, and various initial degrees of initial supersaturation 
were evaluated. 
 
Figure 1.  Chemical structures of (a) naproxen, (b) indomethacin, (c) ibuprofen, (d) 
etodolac 
 





4.1. Brief Literature Review of Supersaturation 
The recent large number of poorly water-soluble compounds in the pharmaceutical industrial 
clinical pipelines has led to an increasing interest in maintenance of supersaturation as a means 
of improving oral bioavailability. Supersaturation may be achieved and sustained with the 
“spring and parachute” approach.
1
 The “spring” dissolves the drug in vivo upon oral 
administration, while the “parachute” sustains the compound in solution by inhibiting 
precipitation or nucleation in the gastrointestinal lumen. Precipitation must be inhibited for 
sufficient time on the order of hours in order for the drug to be absorbed after oral 
administration.
1
 The mechanism of supersaturation has been studied extensively. Supersaturation 
by polymeric ingredients occurs by inhibiting precipitation by two mechanisms: 1) suppressing 
the drug nucleation process by diffusion-controlled nucleation inhibition and/or 2) adsorption of 
polymer onto the crystalline surface, thereby preventing solute molecules from incorporating into 
the growing crystal lattice. The specific supersaturation enhancing properties of polymers, such 
as HPMC, and the mechanisms by which they occur continue to be explored. HPMC appears to 
have the ability to enhance solubility and bioavailability. Ouellet et al.
2
 reported up to two times 
increase in oral bioavailability of solid dabrafenib when administered with HPMC capsules 
compared to gelatin capsules. Upon in-vivo dissolution of the HPMC capsule shell in the 
stomach a solution microenvironment is created that is thought to aid in the dissolution of the 
solid drug and then upon further dilution in the intestinal tract the presence of HPMC keeps the 
drug in solution by promoting supersaturation, which ultimately allows for higher absorption 
compared to  gelatin capsules. 
Yang et al.
3
 observed prolonged supersaturation in a hydrocortisone/HPMC system, in which the 
HPMC induced the formation of a metastable crystal polymorph. Raina et al.
4
 studied the 
crystallization tendencies of six analogues in the dihydropyridine class in the presence of various 
polymers. It was found that polymers with intermediate hydrophilicity/hydrophobicity 
substantially delayed crystallization, while strongly hydrophobic or hydrophilic polymers were 
generally ineffective. Chauhan et al.
5




precipitation in solution and amorphous stabilization in solid state for indomethacin. It was found 
that the rank order of polymer precipitation inhibitory effect for indomethacin was 
polyvinylpyrrolidone K90 > Eudragit (methacrylic acid) E100 > HPMC. This rank order was the 
same in the amorphous stabilization. Infrared (IR) and Raman spectroscopy, and solid state 
NMR showed that the rank order correlated with the strength of the drug polymer interaction.  
Petrusevška et al.
6
 used the solvent shift method to screen various excipients for precipitation 
inhibition of sirolimus in neutral pH buffered water. HPMC 603 and Poloxamer 407 were 
identified as the most effective precipitation inhibitors at 0.1% (w/v) excipient concentration in 
aqueous pH 6.8 buffer. It was also observed that Poloxamer 407 increased the thermodynamic 
solubility of sirolimus, whereas the addition of HPMC 603 did not affect the thermodynamic 
solubility. This difference is explained by the different mechanism by which the excipients 
inhibit precipitation. The tested concentration of Poloxamer 407 was above the critical micelle 
concentration, and the increased thermodynamic solubility was likely a result of sirolimus 
entrapment within micelles. In the presence of HPMC 603, the precipitation inhibition was a 
result of the polymer adsorbing to the surface of crystal’s surface, preventing crystal growth. 
The mechanism by which supersaturation is maintained continues to be explored. Patel et al. 
describe the two-step diffusion-reaction model for crystal growth. The steps comprise of 1) bulk 
diffusion from the solution to the crystal surface and 2) surface integration such that the solute is 
incorporated into the growing crystal lattice. At a high degree of supersaturation (degree of 
supersaturation = 6), it was shown that the crystal growth kinetics of indomethacin was bulk-
diffusion controlled. This was shown by comparing the mass transfer coefficients from 
indomethacin dissolution and crystal growth.
7
 It was also found that the growth crystal kinetics 
of indomethacin is affected by the degree of supersaturation. At high degrees of supersaturation 
(degree of supersaturation between 6 and 9) , the crystal growth rate coefficient was similar to 
that of bulk diffusion-controlled crystal growth. At lower degrees of supersaturation (degree of 
supersaturation = 2), the crystal growth rate coefficient was nearly 10 times less than that of bulk 
diffusion-controlled crystal growth. The decreased crystal growth rate coefficient could be 
explained by a change in the rate-limiting step from bulk diffusion to surface integration. 
Additionally, Patel et al. observed an increase in apparent solubility after crystal growth in 




layer had been deposited on the surface of the seed crystals.
8
 See additional references 
9-21
 which 
the reader might find useful. 
4.2. Choice of Model Compounds 
Four structurally related carboxylic acids of the nonsteroidal anti-inflammatory class were 
chosen as model compounds: naproxen (NAP), indomethacin (IND), ibuprofen (IBU), and 
etodolac (ETO).  
4.3. Specific Goals 
With the increased number of poorly soluble compounds, supersaturation has played an 
important role in enhancing oral bioavailability of poorly water soluble, dissolution limited 
drugs. A greater understanding of the mechanisms and role of polymers that promote 
supersaturation could impact formulation selection in preclinical (PK, toxicology or efficacy) 
studies, clinical studies as well as commercial formulations/products. The specific goals of this 
study are the following: 
 Explore the mechanism and variables by which model compounds show supersaturation 
behavior in the presence of HPMC in aqueous solutions 
 Explore effects of various grades and viscosities of HPMC on etodoloac solubility and 
supersaturation 





5. MATERIALS  
5.1. Model Compounds 
Naproxen was purchased from Sigma-Aldrich Company (St. Louis, Missouri, USA). 
Indomethacin and ibuprofen were purchased from Enzo Life Sciences (Farmingdale, New York, 
USA). Etodolac was purchased from Tokyo Chemical Industry Co., Ltd (Tokyo, Japan). 
Dimethylsulfoxide (DMSO) was purchased from Spectrum (New Brunswick, New Jersey). 
Hydroxypropyl methylcellulose (grades E3 LV, E5 LV, K3 LV, K100 LV, A 4M, and K 4M) 
were supplied from Dow Chemical (Pittsburg, California, USA). Hydrochloric acid, 1.0 normal 
(N) was purchased from J.T. Baker (Center Valley, Pennsylvania, USA). Methanol, acetonitrile, 
0.1% TFA solution in water used in this work were HPLC grade and were obtained from Sigma-
Aldrich Company (St. Louis, Missouri, USA). The chemical structures of the model compounds 
and HPMC are shown in Figure 1 and Figure 2, respectively. The properties of the evaluated 
grades of HPMC are shown in Table 1. The grades of HPMC were chosen based on the filtering 
capabilities of 5% HPMC solutions. 
 
Figure 2. Structure of hydroxypropyl methylcellulose (HPMC) 
Table 1. Properties of evaluated HPMC grades 
HPMC Grade 
Viscosity (mPa s) in 2% 





E3 LV 3 29 8.5 
E5 LV 5 29 8.5 
K3 LV 3 22 8.1 




6. EXPERIMENTAL METHODS 
6.1. Preparation of 0.01 N Hydrochloric Acid Solution 
Water with hydrochloric (HCl) acid at pH 2 was prepared by performing a 100-fold dilution of 1 
M HCl solution into deionized water. 
6.2. Preparation of Hydroxypropyl Methylcellulose (HPMC) in 0.01 N HCl Acid 
Solution 
Solutions with various HPMC concentrations in 0.01 N HCl aqueous solution were prepared on 
weight by weight basis. HPMC was weighed out in appropriate amounts and added to 0.01 N 
HCl aqueous solution to achieve the desired concentration. The mixture was stirred until the 
HPMC dissolved. HPMC solutions were filtered through a 0.45 m polyethersulfone filter, to 
remove particulates. 
6.3. Crystalline Equilibrium Solubility 
Equilibrium solubility was evaluated by adding crystalline active pharmaceutical ingredient 
(API) to each media with 1% DMSO and sonicating for 10 minutes. The reason for the 1% 
DMSO was to simulate kinetic solubility experimental conditions in which as DMSO 
concentrate is diluted 100-fold. The suspensions were shaken at 750 rpm in an Eppendorf 
Thermomixer R (Hamburg, Germany) at 37 °C for up to 1 day and then centrifuged for 10 
minutes at 13,200 rpm. The supernatant was removed, diluted 10-times with an HPLC injection 
solvent composed of either acetonitrile/water (50:50) or ethanol/water (50:50). Standards for 
each compound were prepared by diluting a 1 mg/mL stock solution in DMSO into an HPLC 
injection solvent to achieve concentrations of 1 g/mL, 10 g/mL, and 100 g/mL of API. The 
concentrations of samples and standards were analyzed using the method described in the section 




6.4. Preparation of Supersaturated Solutions/ Kinetic Solubility Studies 
Kinetic solubility of each API in various media was determined using the solvent-shift method.
1
 
The crystalline API  was dissolved in DMSO at various concentrations, and these stock solutions 
were carefully diluted 100-fold into 30 mL of aqueous solution at 37 °C with constant stirring. In 
the evaluated supersaturation method, samples were taken at various time points with a syringe, 
filtered through a GHP (Hydrophilic polypropylene) membrane filter for naproxen and etodolac, 
cellulose membrane filter for indomethacin, nylon filter for ibuprofen, and diluted with 
acetonitrile/water (50:50) or ethanol/water (50:50). The concentrations of samples and standards 
were analyzed using the method described in the section “Concentration Determination by High 
Performance Liquid Chromatography (HPLC)”.   
 Calculation of Degree of Supersaturation 6.4.1.
The degree of supersaturation (DS) of compound is defined as the measured drug concentration 
at a time point (Ct) relative to the equilibrium solubility of crystalline compound (Ceq) in the 
same media. For supersaturation experiments in the presence of HPMC, Ceq is the equilibrium 
solubility of the crystalline compound in 0.01 N with 5% HPMC. For supersaturation 
experiments without HPMC, Ceq is the equilibrium solubility of the crystalline compound in 0.01 
N. 
    
  
   
 Equation 1 
6.5. Concentration Determination by High Performance Liquid Chromatography 
(HPLC) 
High performance liquid chromatography (HPLC) analyses were performed using a Waters 
Alliance system comprising of a 2695 Separation Module and model 2996 photodiode array 
detector (Waters Alliance Instruments, Milford, Massachusetts). The column used was Gemini 
5u C18 110A 150 x 4.60 mm, 5 micron supplied by Phenomenex (Torrance, California). The 
injection volume was 10 L. Detection was by ultraviolet (UV) absorbance at 232 nm for 
naproxen, 256 nm for indomethacin, and 226 nm for etodolac and ibuprofen. Empower (Waters 




The aqueous mobile phase was 0.1% TFA in water, and the organic mobile phase was methanol 
and acetonitrile in a 70:30 (v/v) ratio. The flow rate was 1 mL/min. Elution was performed using 
the solvent gradient from 20% to 100% organic mobile phase in aqueous mobile phase over 10 
minutes. 
6.6. Solid State Characterization by X-Ray Powder Diffraction (XRPD) 
The solids from the equilibrium solubility studies and supersaturation/kinetic solubility studies 
were harvested by filtration. Solids from equilibrium solubility studies were collected after 
shaking for 1 day at 37 ºC. In order to collect remaining solids from kinetic solubility studies, 
separate kinetic solubility studies were set up at an initial degree of supersaturation of 25 or 50 to 
force and ensure sufficient precipitation. Remaining suspensions from studies were centrifuged 
at 13,200 rpm for 10 minutes through a 0.45 m nylon filter.  In the kinetic solubility studies any 
solid material that precipitated was collected at the 30 minute time point, 3 hour time point, and 
24 hour time point (when applicable). Solid samples were analyzed by X-ray powder 
diffracometer for crystallinity and polymorphic form. In a typical XRPD experiment, powder 
was deposited in the hollow of an aluminum holder equipped with a zero background plate with 
the aid of glass slide. Diffraction data (Cu Kα, λ = 1.5418 Å) were collected on a PANanalytical 
XPERT-PRO (PANalytical B.V., Almelo, Netherlands) diffractometer. The generator was 
operated at 45 kV and 40 mA. Slits used: Soller 0.02 rad., antiscatter 1.0°, and divergence. Scans 
were performed from 2 to 40° 2θ with 0.0084° step size with varying scan rates. Data analysis 




7. RESULTS  
7.1. Equilibrium Solubility of Crystalline API in Absence and Presence of 5% 
HPMC E3 LV in 0.01 N HCl in Water at 37 °C with 1% DMSO 
The equilibrium crystalline solubility of NAP, IND, IBU, and ETO were determined in the 
absence and presence of 5% HPMC E3 LV pre-dissolved in 0.01 N HCl with 1% DMSO. The 
solubility results are shown in Table 2. The presence of HPMC enhances the equilibrium 
solubility of NAP by about 2-fold (26 to 60 g/mL), of IBU by about 1.6-fold (54 to 86 g/mL), 
and 4-fold for IND (2 to 8 g/mL). There was smaller increase in equilibrium solubility (109 to 
123 g/mL) for ETO in the presence of HPMC compared to the other three acids.  
Table 2. Equilibrium solubility values of four crystalline APIs in the absence and presence 
of 5% HPMC E3 LV in 0.01 N HCl with 1% DMSO in water at 37 ºC 
 Equilibrium Solubility of Crystalline API (g/mL) 
API 0.01 N HCl 5% HPMC E3 LV in 0.01 N HCl 
Naproxen 26 60 
Indomethacin 2 8 
Ibuprofen 54 86 
Etodolac 109 123 
 
7.2. Solid-State Characterization by XRPD on Remaining Solid in Equilibrium 
Solubility Studies 
The remaining solid from equilibrium solubility studies in the absence and presence of 5% 
HPMC E3 LV in 0.01 N HCl were collected and analyzed for polymorphic form change by 
XRPD for all model compounds. In the case of etodolac, additional HPMC grades were 
evaluated (still at 5%): HPMC E5 LV and HPMC K3 LV. Figure 3, Figure 4, Figure 5, and 
Figure 6 show the XRPD scans for NAP, IND, IBU, and ETO, respectively, and each figure has 




measurements. For all compounds, the remaining solids in all equilibrium solubility studies were 
crystalline and identical to the initial crystalline form.  
 Naproxen 7.2.1.
 
Figure 3. PXRD scans of naproxen (a) initial crystalline naproxen, harvested from 
equilibrium solubility studies at 37 °C in water with (b) 0.01 N HCl, and (c) 




Figure 4. PXRD scans of indomethacin (a) initial crystalline indomethacin, harvested from 
equilibrium solubility studies at 37 °C in water with (b) 0.01 N HCl, and (c) 0.01 
N HCl with 5% HPMC E3 LV 
 






























Figure 5. PXRD scans of ibuprofen (a) initial crystalline ibuprofen, harvested from 
equilibrium solubility studies at 37 °C in water with (b) 0.01 N HCl, and (c) 
0.01 N HCl with 5% HPMC E3 LV 
 Etodolac 7.2.4.

























Figure 6. PXRD scans of etodolac (a) neat crystalline etodolac, harvested from equilibrium 
solubility studies at 37 °C in water with 0.01 N HCl (b) without HPMC, (c) with 
5% HPMC E3 LV, (d) with 5% HPMC E5 LV, (e) with 5% HPMC K3 LV 
7.3. Effect of HPMC on Supersaturation Maintenance  
 Naproxen 7.3.1.
7.3.1.1. Supersaturation Maintenance 
Supersaturation maintenance was evaluated for naproxen (NAP) in the presence and absence of 
5% HPMC E3 LV in water with 0.01 N HCl at 37 ºC for up to 3 hours. Figure 7 shows the 
concentration-time profiles and supersaturation-time profiles for NAP. The initial degree of 
supersaturation was 5. In the absence and presence of HPMC E3 LV there was observed 
immediate precipitation of NAP. In the absence of HPMC the dissolved concentration of NAP 
immediatey decreased but was still above the equilibrium solubility value and a degree of 
supersaturation of approximately 1.5 was maintained throughout the course of the experiment. In 
the presence of HPMC E3 LV the dissolved concentration of NAP immediatey decreased but 


























was still above the equilibrium solubility value and a degree of supersaturation of approximately 
2.3 was observed at 30 minutes, and 1.9 after 3 hours.. 
 
Figure 7. Concentration-time profiles (left) and supersaturation-time profiles (right) of 
dissolved naproxen in water in the absence (■) and presence (▲) of 5% HPMC 
E3 LV in 0.01 N HCl and 1% DMSO at 37 ºC.  Total naproxen concentration 
was 130 g/mL in the absence of HPMC E3 LV and 300 g/mL in the presence 
of HPMC E3 LV. The initial degree of supersaturation was 5. 
7.3.1.2. Solid-state Characterization by XRPD 
The precipitated solids from NAP kinetic solubility studies under forced precipitation 
conditions (refer to Section 6.6) were harvested by filtration and analyzed 
for crystallinity by XRPD.  
Figure 8 compares the XRPD scans of initial crystalline NAP, precipitated solid material from 
kinetic solubility studies in in the absence and presence of 5% HPMC E3 LV in 0.01 N HCl at 30 
minutes and 3 hours of the experiment.  The results show the precipitated solid in the absence 
and presence of HPMC E3 LV is of a different form than the initial crystalline form of NAP. In 
the absence of HPMC E3 LV, precipitated NAP shows to be a different crystalline form than the 
intial form. Based on the lack of sharpness in the later peaks, not only might a new polymorph of 
naproxen be formed but some amorphous characteristics are seen in the solids in the presence of 



































































Figure 8. PXRD scans of naproxen (a) neat crystalline naproxen harvested from kinetic 
solubility studies under forced precipitation conditions at 37 °C in water with 
(b) 0.01 N HCl at 30 minutes, (c) 0.01 N HCl at 3 hours, (d) 0.01 N HCl with 
5% HPMC E3 LV at 30 minutes, (e) 0.01 N HCl with 5% HPMC E3 LV at 3 
hours 
 Indomethacin 7.3.2.
7.3.2.1. Supersaturation Maintenance 
Supersaturation maintenance was evaluated for indomethacin (IND) in the presence and absence 
of 5% HPMC E3 LV in water with 0.01 N HCl at 37 ºC for up to 3 hours. Figure 9 shows the 
concentration-time profiles and supersaturation-time profiles for IND. The initial degree of 
supersaturation was 5. In the absence of HPMC there was no  IND precipitation for 30 minutes, 
but after 3 hours precipitation occurred, and the dissolved IND concentration was above the 
equilibrium solubility with a degree of supersaturation of approximately 2.5. In the presence of 




























HPMC E3 LV there was no observed precipitation of IND and the degree of supersaturation of 5 
was maintained throughout the course of the experiment. 
 
Figure 9. Concentration-time profiles (left) and supersaturation-time profiles (right) of 
dissolved indomethacin in water in the absence (■) and presence (▲) of 5% 
HPMC E3 LV in 0.01 N HCl and 1% DMSO at 37 ºC.  Total indomethacin 
concentration was 10 g/mL in the absence of HPMC E3 LV and 40 g/mL in 
the presence of HPMC E3 LV. The initial degree of supersaturation was 5. 
7.3.2.2. Solid-state Characterization by XRPD 
The precipitated solids from IND kinetic solubility studies under forced precipitation conditions 
(refer to Section 6.6)were harvested by filtration and analyzed for crystallinity by XRPD. Figure 
10 compares the XRPD scans of initial crystalline IND, precipitated solid material from kinetic 
solubility studies in the absence and presence of 5% HPMC E3 LV in 0.01 N HCl at 30 minutes 
and 3 hours of the experiment.  The results show that the IND precipitated solid forms in the 


































































Figure 10. PXRD scans of indomethacin (a) neat crystalline indomethacin harvested from 
kinetic solubility studies under forced precipitation conditions at 37 °C in water 
with (b) 0.01 N HCl at 30 minutes, (c) 0.01 N HCl at 3 hours, (d) 0.01 N HCl 
with 5% HPMC E3 LV at 30 minutes, (e) 0.01 N HCl with 5% HPMC E3 LV at 
3 hours 
 Ibuprofen 7.3.3.
7.3.3.1. Supersaturation Maintenance 
Supersaturation maintenance was evaluated for ibuprofen (IBU) in the presence and absence of 
5% HPMC E3 LV in water with 0.01 N HCl at 37 ºC for up to 3 hours. Figure 11 shows the 
concentration-time profiles and supersaturation-time profiles for IBU. The initial degree of 
supersaturation was 5. In the absence and presence of HPMC E3 LV there was observed 
immediate precipitation of IBU. In the absence of HPMC the dissolved concentration of IBU 
immediatey decreased to the equilibrium solubility value within 10 minutes. In the presence of 
HPMC E3 LV the dissolved concentration of IBU immediately decreased but was still above the 




























equilibrium solubility value and a degree of supersaturation of approximately 3.0 was maintained 
throughout the course of the experiment.. 
 
 
Figure 11. Concentration-time profiles (left) and supersaturation-time profiles (right) of 
dissolved ibuprofen in water in the absence (■) and presence (▲) of 5% HPMC 
E3 LV in 0.01 N HCl and 1% DMSO at 37 ºC.  Total ibuprofen concentration 
was 250 g/mL in the absence of HPMC E3 LV and 450 g/mL in the 
presence of HPMC E3 LV. The initial degree of supersaturation was 5. 
7.3.3.2. Solid-state Characterization by XRPD 
The precipitated solids from IBU kinetic solubility studies under forced precipitation conditions 
(refer to Section 6.6)were harvested by filtration and analyzed for crystallinity by XRPD. Figure 
12 compares the XRPD scans of initial crystalline IBU, precipitate from kinetic solubility studies 
in in the absence and presence of 5% HPMC E3 LV in 0.01 N HCl at 30 minutes and 3 hours of 
the experiment. The scans show that in the absence of HPMC E3 LV, the precipitated solids are 
of the same crystalline form as the initial crystalline IBU, although there is some loss of 
sharpness in some of the peaks. In the presence of HPMC E3 LV, there is some amorphous 
character in the precipitated solid but the peaks seen in these materials (presumably a mixture) 




































































Figure 12. PXRD scans of ibuprofen (a) neat crystalline ibuprofen, harvested from kinetic 
solubility studies under forced precipitation conditions at 37 °C in water with  
(b) 0.01 N HCl at 30 minutes, (c) 0.01 N HCl at 3 hours, (d) 0.01 N HCl with 
5% HPMC E3 LV at 30 minutes, (e) 0.01 N HCl with 5% HPMC E3 LV at 3 
hours 
 Etodolac 7.3.4.
7.3.4.1. Supersaturation Maintenance 
Supersaturation maintenance was evaluated for etodolac (ETO) in the presence and absence of 
5% HPMC E3 LV in water with 0.01 N HCl at 37 ºC for up to 3 hours. Figure 13 shows the 
concentration-time profiles and supersaturation-time profiles for ETO. The initial degree of 
supersaturation was 5. In the absence of HPMC there was no precipitation for 5 minutes, but 
after 10 minutes precipitation occured and the dissolved ETO concentration decreased to near the 
equilibrium solubility value. In the presence of HPMC E3 LV there was no observed 


























precipitation of ETO and the degree of supersaturation of 5 was maintained throughout the 
course of the experiment. 
 
Figure 13. Concentration-time profiles (left) and supersaturation-time profiles (right) of 
dissolved etodolac in water in the absence (■) and presence (▲) of 5% HPMC 
E3 LV in 0.01 N HCl and 1% DMSO at 37 ºC.  Total etodolac concentration 
was 550 g/mL in the absence of HPMC E3 LV and 625 g/mL in the presence 
of HPMC E3 LV. The initial degree of supersaturation was 5. 
7.3.4.2. Solid-state Characterization by XRPD 
The precipitate from ETO kinetic solubility studies under forced precipitation conditions 
(refer to Section 6.6)were harvested by filtration and analyzed for 
crystallinity by XRPD.  
Figure 14 compares the XRPD scans of initial crystalline ETO, precipitates from kinetic 
solubility studies in in the absence and presence of 5% HPMC E3 LV in 0.01 N HCl at 30 
minutes and 3 hours of the experiment. The scans show that in the absence of HPMC E3 LV, the 
precipitated solid material shows some crystalline characteristics but is not identical to the initial 



































































Figure 14. PXRD scans of etodolac (a) neat crystalline etodolac, harvested kinetic 
solubility studies under forced precipitation conditions at 37 °C in water with  
(b) 0.01 N HCl at 30 minutes, (c) 0.01 N HCl at 3 hours, (d) 0.01 N HCl with 
5% HPMC E3 LV at 30 minutes, (e) 0.01 N HCl with 5% HPMC E3 LV at 3 
hours 
7.4. Effect of Various Grades of HPMC on Supersaturation Maintenance in 
Etodolac 
 Effect of HPMC Grade on Apparent Equilibrium Solubility of Etodolac 7.4.1.
The equilibrium solubility of crystalline ETO was determined as a function of various grades of 
HPMC pre-dissolved at 5% in water with 0.01 N HCl. The equilibrium crystalline solubility 
values are shown in Table 3. There was some effect on equilibrium solubility of ETO in the 
presence of the evaluated grades of HPMC. The equilibrium solubility values were 109 g/mL, 
123 g/mL, 105 g/mL, and 115 g/mL in the absence of HPMC, 5% HPMC E3 LV, 5% 
HPMC E5 LV, and 5% HPMC K3 LV, respectively. 



























Table 3. Equilibrium solubility values of crystalline etodolac in the absence and 
presence of various grades of 5% HPMC in 0.01 N HCl in water at 37 ºC with 
1% DMSO 
Aqueous Media with 1% DMSO 
Equilibrium Solubility of 
Crystalline Etodolac  
g/mL) 
0.01 N HCl 109 
0.01 N HCl with 5% HPMC E3 LV 123 
0.01 N HCl with 5% HPMC E5 LV 105 
0.01 N HCl with 5% HPMC K3 LV 115 
 Effect of HPMC Grade on Supersaturation of Etodolac  7.4.2.
7.4.2.1. Supersaturation Maintenance in Various Grades of HPMC 
Supersaturation maintenance was evaluated for etodolac in the absence and presence of 5% 
HPMC E3 LV, 5% HPMC E5 LV, and 5% HPMC K3 LV in 0.01 N HCl at 37 ºC for up to 3 
hours. Figure 15 shows the concentration-time profiles and supersaturation-time profiles for ETO 
in the evaluated grades of HPMC. The initial degree of supersaturation was 5. In the absence of 
HPMC there was no precipitation for 5 minutes, but after 10 minutes precipitation occured and 
the dissolved ETO concentration near the equilibrium solubility value. In the presence of each 
grade of HPMC there was no observed precipitation of ETO and the degree of supersaturation of 





Figure 15. Concentration-time profiles (left) and supersaturation-time profiles (right) of 
dissolved etodolac in water in the absence (■) and presence of 5% HPMC E3 
LV(▲), 5% HPMC E5 LV(♦), and 5% HPMC K3 LV(○) in 0.01 N HCl and 
1% DMSO at 37 ºC.  Total etodolac concentration was 550 g/mL in the 
absence of HPMC and 625 g/mL in the presence of HPMC. The initial degree 
of supersaturation was 5. 
7.4.2.2. Solid-state Characterization by XRPD 
 HPMC E5 LV 7.4.3.
The precipitates from ETO kinetic solubility studies under forced precipitation conditions 
(refer to Section 6.6)in 5% HPMC E5 LV were harvested by filtration and 
analyzed for crystallinity by XRPD.  
Figure 16 compares the XRPD scans of initial crystalline ETO and the precipitates from the 
kinetic solubility studies in in the absence and presence of 5% HPMC E5 LV in 0.01 N HCl at 30 
minutes and 3 hours of the experiment. The scans show that in the absence of HPMC E5 LV the 
precipitated solid materials show some crystalline characteristics, but are not polymorphically 
identical to the initial crystalline form of ETO. In the presence of HPMC E5 LV, the precipitated 
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Figure 16. PXRD scans of etodolac (a) neat crystalline etodolac, harvested from kinetic 
solubility studies under forced precipitation conditions at 37 °C in water with 
(b) 0.01 N HCl at 30 minutes, (c) 0.01 N HCl at 3 hours, (d) 0.01 N HCl with 
5% HPMC E5 LV at 30 minutes, (e) 0.01 N HCl with 5% HPMC E5 LV at 3 
hour 
 HPMC K3 LV 7.4.4.
The precipitates from ETO kinetic solubility studies under forced precipitation conditions (refer 
to Section 6.6) in 5% HPMC K3 LV were harvested by filtration and analyzed for crystallinity 
by XRPD. Figure 17 compares the XRPD scans of initial crystalline ETO and theprecipitates 
from the kinetic solubility studies in in the absence and presence of 5% HPMC K3 LV in 0.01 N 
HCl at 30 minutes, 3 hours, and 24 hours of the experiment. The scans show that in the absence 
of HPMC K3 LV the precipitated solid materials show some crystalline characteristics, but are 
not identical to the initial crystalline form of ETO. In the presence of HPMC K3 LV the 
precipitated solid materials shows some amorphous characteristics with some  peaks 
corresponding with the intial starting crystalline material. 































Figure 17. PXRD scans of etodolac (a) neat crystalline etodolac, harvested from kinetic 
solubility studies under forced precipitation conditions at 37 °C in water with  (b) 
0.01 N HCl at 30 minutes, (c) 0.01 N HCl at 3 hours, (d) 0.01 N HCl with 5% 
HPMC K3 LV at 30 minutes, (e) 0.01 N HCl with 5% HPMC K3 LV at 3 hour, 
(f) 0.01 N HCl with 5% HPMC K3 LV at 24 hour 
7.5. Effect of Various Initial Degrees of Supersaturation on Observed 
Precipitation Time in Supersaturation in Etodolac 
Supersaturation maintenance at various initial degrees of supersaturation was evaluated for 
etodolac in 0.01 N HCl with pre-dissolved 5% HPMC K3 LV at 37 ºC for up to 24 hours. Figure 
18 shows the concentration-time profiles and supersaturation-time profiles for ETO at initial 
degrees of supersaturation of 5, 7, and 10. Precipitation occurred with degrees of supersaturation 
of 7 and 10, but no precipitation occured with a degree of supersaturation of 5. Table 4 lists the 
time at which precipitation was observed at various initial degrees of supersaturation. At an 
initial degree of supersaturation of 5, ETO remains in solution with no precipitation throughout 
the course of the 24-hour experiment. At an initial degree of supersaturation of 7, ETO remains 
in solution with no precipitation for 3 hours, but precipitation was observed between 3 and 6 


























hours with the solution concentration maintained above the equilibrium solubility and degrees of 
supersaturation of approximately 6 and 3 observed at 6 and 24 hours, respectively. At an initial 
degree of supersaturation of 10, precipitation of ETO is observed immediately with the solution 
concentration maintained above the equilibrium solubility and degrees of supersaturation of 
approximately 3 observed between 3 and 24 hours. 
 
Figure 18. Concentration-time profiles (left) and supersaturation-time profiles (right) of 
dissolved etodolac in water with 5% HPMC K3 LV and 0.01 N HCl and 1% 
DMSO at 37 ºC.  The initial degrees of supersaturation were 5 (♦), 7 (■), and 
10 (▲). Dashed curves indicate time at which precipitation was observed. 
Table 4. Time of observed precipitation of etodolac with various initial degrees of 
supersaturation in water with 5% HPMC K3 LV and 0.01 N HCl and 1% 
DMSO at 37 ºC 
Initial Degree of Supersaturation Time of Observed Precipitation 
5 None up to 24 hoursa 
7 3 hours 
10 Immediate 
a 
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8.1. Increased Equilibrium Solubility of Crystalline API in the Presence of 
HPMC 
The apparent increased equilibrium solubility of crystalline NAP, IND, IBU, and ETO under 
aqueous acidic conditions with 5% HPMC E3 LV indicates a favorable solution interaction 
between the unionized drugs studied and HPMC in solution. The favorable interaction could be 
explained by a decrease in chemical potential of the compounds in solution relative to the 
chemical potential in the absence of HPMC. Equation 2 shows the relationship between the 
chemical potential (i) of a chemical species in solution, free energy (G), and the number of 
dissolved molecules (Ni) in solution at constant temperature (T) and pressure (P). For each of the 
three compounds, in the equilibrium solubility measurement there was no observed change in 
polymorphic form in the remaining crystalline solid material compared to the initial crystalline 
solid, suggesting a constant free energy of the solid during the solubility experiment. The 
observed increase in solubility of crystalline drugs with pre-dissolved HPMC along with a 
constant free energy of the crystalline solid means that the chemical potential of the drug in 
solution is reduced in the presence of HPMC.  
   (
  
   
)
      
 Equation 2 
8.2. Observed Supersaturation of Compounds in the Presence of HPMC 
In the supersaturation/kinetic solubility experiments  in the presence of 5% HPMC E3 
LV, all four of the compounds (NAP, IND, IBU, and ETO), were shown to maintain 
supersaturation for up to 3 hours. The alteration in the crystalline form of the precipitate and in 
most cases the amorphous character of the precipitate suggests that HPMC molecules may 
adsorb onto the surface of a solid precipitate preventing the initiation of crystallization to their 
most apparent stable form or, perturbing the growth of a seed crystals or preventing the 
formation of crystalline material altogether. The precipitated amorphous solid form has a higher 




solubility in solution increases. In the absence of HPMC, the precipitation of the compounds 
remains highly crystalline, and supersaturation is not maintained. The data suggests that 
supersaturation is generated and maintained with HPMC as a crystallization inhibitor, yielding a 
solid form of higher free energy, which results in increased solubility.  
There appears to be some correlation between higher degree of supersatursaturation maintained 
and increased amorphous character in the precipitated material. In the case of both ETO and 
IND, the precipitation in the presence of HPMC yields a completely amorphous material, and 
precipitation is not observed after 3 hours with these compounds in the presence of HPMC, and a 
degree of supersaturation of 5 is maintained. In the case of NAP and IBU, the precipitation in the 
presence of HPMC showed to be a mixture of crystalline and amorphous material, and 
precipitation was observed at the initial time point and the degree of supersaturation did not 
exceed 3 for both compounds. 
 Varying Grade and Molecular Weight of HPMC Resulted in Some 8.2.1.
Differences in Etodolac Crystalline Equilibrium Solubility and 
Supersaturation  
The data indicates that the presence of HPMC is more important than the molecular weight or 
grade. HPMC appears to enhance supersaturation in etodolac under acidic conditions by 
inhibiting crystallization and forming amorphous solid. The formation of amorphous solid could 
be a result of polymer molecules adsorbing onto the surface of a precipitate. The exact chemistry 
of HPMC or the viscosity of HPMC-containing solutions does not appear to affect the ability of 
etodolac to generate and maintain supersaturation per se. There might be some indication that the 
grade affects the amount of amorphous material that is formed, as precipitation in the presence of 
5% HPMC E3 LV is completely amorphous, while precipitation in the presence of 5% HPMC 
E5 LV or 5% HPMC K3 LV show some crystallinity. 
 Increased Initial Degrees of Supersaturation Resulted in Decreased Time of 8.2.2.
Observed Precipitation of Etodolac 
Under acidic conditions with pre-dissolved 5% HPMC K3 LV, an increased initial degree of 
supersaturation (within the range of 5-10 studied) appears to be a driving force for precipitation 
of etodoloc. At increasing degrees of supersaturation the solution free energy of etodolac 




supersaturatin increases the time to precipitate decreases. Also, once a seed crystal or amorphous 
solid is formed in a highly supersaturated solution the chance of redissolution is reduced and the 
chance of further solid growth is increased given the increased number of nucleation sites.  
8.3. Mechanism of Supersaturation in Compounds in the Presence of HPMC is 
Increased Equilibrium Solubility and Crystallization Inhibition 
In the cases of naproxen, indomethacin, and ibuprofen there is a significant relative increase in 
equilibrium solubility in the presence of 5% HPMC E3 LV without a change in crystalline form. 
The relative increase of equilibrium solubility in the presence of 5% HPMC E3 LV of etodolac 
was less, compared to the other compounds. In kinetic solubility experiments in the presence of 
5% HPMC E3 LV, the harvested precipitates showed altered crystalline states or amorphous 
character relative to the initial crystalline form. This suggests that the mechanism of 
supersaturation in this series of compounds is a combination of increased equilibrium solubility 
and crystallization inhibition in the presence of HPMC. 
The case of etodolac is different in that there was only a slight relative increase in equilibrium 
solubility in the presence of HPMC. However, the precipitation from kinetic solubility 
experiments show amorphous characteristics, suggesting that etodolac relies largely on 
crystallization inhibition to sustain supersaturation in the presence of HPMC.  
8.4. Signifigance of Research 
According to the findings, the presence of HPMC appears to provide favorable conditions for 
solubilizing and generating supersaturation in the neutral form of the evaluated crystalline 
carboxylic acids. The solubilizing effect of HPMC could be expanded and applied in the 
formulation of other poorly water-soluble compounds. HPMC could be added within a tablet 
formulation to provide supersaturation conditions upon in vivo oral administration and 
potentially improving oral bioavailability. The HPMC could also be further co-processed with 
the drug to generate amorphous solid dispersion material using a spray-drying manufacturing 
process. The work also confirms the conclusions of Ouellet et al
2
, that the use of HPMC capsules 






Supersaturation was shown to be maintained to varying extents in four structurally-related 
carboxylic acids drugs (naproxen, indomethacin, ibuprofen, and etodolac) under aqueous acidic 
conditions in the presence of HPMC. In three of the four compounds (naproxen, indomethacin, 
and ibuprofen), the mechanism by which supersaturation occurred was both by increased 
equilibrium solubility, and alteration in crystal form or crystallization inhibition in the presence 
of HPMC. Precipitates in the presence of HPMC often showed amorphous character, indicating a 
form change. In etodolac, there was only a small observed relative increase in equilibrium 
solubility, but a loss of crystallinity in the kinetic solubility studies, suggesting that etodolac 
sustains supersaturation largely by crystallization inhibition. Further studies with etodolac 
showed that the molecular weight or grade of HPMC has some effect on the degree of 
supersaturation but that the effect could not be correlated to chemistry or the viscosity of the 
solution. For etodolac over the range of 5-10 studied in the initial degree of supersaturation, an 
initial degree of supersaturation of 5 was optimal in maintaining supersaturation. Increased initial 
degrees of supersaturation resulted in decreased onset time of precipitation. The studies suggest 
that HPMC could potentially increase oral bioavailabilty by generating supersaturation of a 
poorly water-soluble compound upon in vivo oral administration.  
Additional contributions could be made in further investigating the interactions between HPMC 
and the compounds. Each compound showed different maintained degrees of supersaturation, 
possibly due to different interaction strengths with HPMC. A correlation could be determined 
between the quantification of crystallinity in precipitate and the degree of supersaturation over a 
time-course experiment. Further evaluations could be made with ETO, to explore its interactions 
between the different grades of HPMC, as different grades showed different levels of 
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